May 21, 2018 7:03 PM ET


Company Overview of Bio Products Laboratory Ltd.

Company Overview

Bio Products Laboratory Ltd. processes and manufactures plasma-derived products for healthcare professionals and patients in the United Kingdom and internationally. It offers human coagulation factors, immunoglobulins, and albumin solutions. The company also produces a small volume of products (on request) for niche markets. Bio Products Laboratory Ltd. was founded in 1950 and is based in Elstree, United Kingdom with operations in Durham, North Carolina. Bio Products Laboratory Ltd. operates as a subsidiary of Bio Products Laboratory Holding Limited.

Dagger Lane

Elstree,  WD6 3BX

United Kingdom

Founded in 1950


44 20 8957 2200


44 20 8957 2601

Key Executives for Bio Products Laboratory Ltd.

Chief Executive Officer
Age: 46
Chief Operating Officer
Medical Director
Vice President of Global Medical
Compensation as of Fiscal Year 2017.

Bio Products Laboratory Ltd. Key Developments

FDA Approves Bio Products Laboratory's Gammaplex® 10% for Treatment of Primary Immunodeficiency and Chronic Immune Thrombocytopenic Purpura

Bio Products Laboratory Limited announced that the U.S. Food and Drug Administration (FDA) has approved Gammaplex® 10% (immune globulin intravenous [human], 10% liquid) for the treatment of primary immunodeficiency (PI) and chronic immune thrombocytopenic purpura (ITP) in adults. Gammaplex 10% is made with the same process as BPL's previously approved intravenous immunoglobulin (IVIG) treatment, Gammaplex® 5% (immune globulin intravenous [human], 5% liquid). Gammaplex 10% is more concentrated than Gammaplex 5%, with an immune globulin G (IgG) concentration of 100g/L, and is stabilized with glycine. The approval was based on a two-phase, crossover bioequivalence study comparing Gammaplex 10% and Gammaplex 5% in 33 adult patients with PI. The primary endpoint of bioequivalence between the products was achieved and trough levels of IgG were well maintained throughout the study. This study is the first direct comparison of 10% and 5% IVIG products in the treatment of PI. In the study both Gammaplex 10% and Gammaplex 5% infusion rates were increased incrementally at 15-minute intervals if tolerated by the subject. No notable differences were observed in the safety and tolerability between the products and the Gammaplex 10% infusion rate was increased per the prescribed infusion schedule to maximum infusion rate in 96% of infusions. The mean infusion time for Gammaplex 10% in adult patients was 1 hour and 51 minutes, which was 57 minutes faster than Gammaplex 5%. The most common adverse reactions in adult subjects receiving Gammaplex 10% in the PI clinical trial were headache (12.5% of subjects), migraine (6.3%), and pyrexia (6.3%). There were no serious product-related adverse reactions in the PI clinical trial. The safety of Gammaplex 10% has not been established in patients with ITP. The safety profile for Gammaplex 5% has been studied in subjects with ITP, and it is anticipated that the safety profile for both formulations are comparable for ITP patients. The most common adverse reactions in adult subjects receiving Gammaplex 5% in the chronic ITP clinical trial were headache, vomiting, nausea, pyrexia, arthralgia, and dehydration. Serious adverse reactions observed in clinical trial subjects with ITP were headache, vomiting and dehydration. Primary immunodeficiencies are a constellation of immune disorders that can negatively impact the body's ability to fight infection. In some primary immunodeficiencies the immune system does not manufacture adequate quantities of antibodies such as IgG. Gammaplex 10% acts as replacement therapy in these patients.

Bio Products Laboratory Ltd. Wins Multiple Awardees Contract for Supplying Factor X and Porcine Factor VIII

Bio Products Laboratory Ltd. won a multiple awardees contract award from The Secretary of State for Health acting as part of the Crown through the Commercial Medicines Unit (part of the Department of Health) for the supply of Factor X and Porcine Factor VIII (Contract Award Notice No.: 2016/S 108-193273). The lowest offer is GBP 14.4 million and the highest offer is GBP 17.6 million (excluding VAT).

Similar Private Companies By Industry

Company Name Region
Abcellute Ltd. Europe
Abcodia Ltd. Europe
Abeterno Ltd. Europe
Abgentis Limited Europe
Achilles Therapeutics Ltd. Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Bio Products Laboratory Ltd., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at